Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naphthazarin is a naturally occurring **quinone compound** with the molecular formula C10H6O4, known chemically as **5,8-dihydroxy-1,4-naphthoquinone**. As a small molecule, it acts primarily via induction of the **Nrf2/ARE pathway**, promoting antioxidant and detoxifying gene expression (including HO1 and TrxR1), and confers neuroprotection against glutamate-induced neuronal cell death. Mechanistically, it triggers apoptosis through oxidative stress, activation of mitochondrial apoptosis-inducing factor (AIF), depolymerization of microtubules, p53-dependent p21 activation, and interference with lysosomal function[3][5][9][11]. Naphthazarin demonstrates **anti-tumor** and **antineoplastic** effects, has been shown to **protect neurons** in preclinical neurological models, and possesses additional roles as an antibacterial agent, acaricide, and plant metabolite[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphthazarin.